Dynavax Technologies (DVAX) Stock Rating Lowered by BidaskClub
Dynavax Technologies (NASDAQ:DVAX) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Friday.
Other research analysts have also recently issued research reports about the stock. Cowen restated a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Friday, November 3rd. Royal Bank of Canada restated an “outperform” rating and set a $28.00 target price (up previously from $26.00) on shares of Dynavax Technologies in a report on Monday, September 25th. Cantor Fitzgerald increased their target price on shares of Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Thursday, November 9th. Zacks Investment Research cut shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Finally, ValuEngine cut shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Three analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $25.17.
Shares of Dynavax Technologies (DVAX) opened at $15.42 on Friday. Dynavax Technologies has a 12-month low of $3.70 and a 12-month high of $24.45. The stock has a market cap of $934.70, a price-to-earnings ratio of -7.87 and a beta of 1.31.
Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the prior year, the firm earned ($0.90) earnings per share. The firm’s revenue was down 68.8% compared to the same quarter last year. equities analysts anticipate that Dynavax Technologies will post -1.72 earnings per share for the current fiscal year.
In other Dynavax Technologies news, insider Robert Coffman sold 7,500 shares of the stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total value of $141,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP David Louis Johnson sold 3,092 shares of the stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total transaction of $57,511.20. Following the completion of the sale, the vice president now owns 7,780 shares of the company’s stock, valued at approximately $144,708. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.
A number of hedge funds have recently made changes to their positions in DVAX. PointState Capital LP acquired a new stake in Dynavax Technologies in the second quarter valued at $13,510,000. Lord Abbett & CO. LLC acquired a new stake in Dynavax Technologies in the second quarter valued at $7,777,000. GMT Capital Corp lifted its stake in Dynavax Technologies by 28.2% in the second quarter. GMT Capital Corp now owns 3,005,137 shares of the biopharmaceutical company’s stock valued at $29,450,000 after acquiring an additional 660,637 shares during the last quarter. Bain Capital Public Equity Management LLC acquired a new stake in Dynavax Technologies in the second quarter valued at $4,741,000. Finally, JPMorgan Chase & Co. lifted its stake in Dynavax Technologies by 344.8% in the second quarter. JPMorgan Chase & Co. now owns 505,227 shares of the biopharmaceutical company’s stock valued at $4,876,000 after acquiring an additional 391,632 shares during the last quarter. Hedge funds and other institutional investors own 70.54% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Dynavax Technologies (DVAX) Stock Rating Lowered by BidaskClub” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/dynavax-technologies-dvax-stock-rating-lowered-by-bidaskclub/1813039.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.